S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales: Mayer, C, Cooper, D, Redfern, A, Geng, X, Shi, J, Zutphen-van Geffen, M, Kuan, I, Koek, K, Kastrissios, H, Patel, K, Davis, M, Yue, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812069/
http://dx.doi.org/10.1097/01.HS9.0000821444.06029.7c
_version_ 1784644568889688064
author Mayer, C
Cooper, D
Redfern, A
Geng, X
Shi, J
Zutphen-van Geffen, M
Kuan, I
Koek, K
Kastrissios, H
Patel, K
Davis, M
Yue, P
author_facet Mayer, C
Cooper, D
Redfern, A
Geng, X
Shi, J
Zutphen-van Geffen, M
Kuan, I
Koek, K
Kastrissios, H
Patel, K
Davis, M
Yue, P
author_sort Mayer, C
collection PubMed
description
format Online
Article
Text
id pubmed-8812069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88120692022-02-18 S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE Mayer, C Cooper, D Redfern, A Geng, X Shi, J Zutphen-van Geffen, M Kuan, I Koek, K Kastrissios, H Patel, K Davis, M Yue, P Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8812069/ http://dx.doi.org/10.1097/01.HS9.0000821444.06029.7c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Presentations
Mayer, C
Cooper, D
Redfern, A
Geng, X
Shi, J
Zutphen-van Geffen, M
Kuan, I
Koek, K
Kastrissios, H
Patel, K
Davis, M
Yue, P
S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title_full S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title_fullStr S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title_full_unstemmed S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title_short S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
title_sort s119: preliminary results of a phase 1 study in healthy subjects administered inclacumab, a fully human igg4 anti-p-selectin monoclonal antibody in development for treatment of sickle cell disease
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812069/
http://dx.doi.org/10.1097/01.HS9.0000821444.06029.7c
work_keys_str_mv AT mayerc s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT cooperd s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT redferna s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT gengx s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT shij s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT zutphenvangeffenm s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT kuani s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT koekk s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT kastrissiosh s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT patelk s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT davism s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease
AT yuep s119preliminaryresultsofaphase1studyinhealthysubjectsadministeredinclacumabafullyhumanigg4antipselectinmonoclonalantibodyindevelopmentfortreatmentofsicklecelldisease

Ejemplares similares